Search Results

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”).

Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).

Cybin Inc. today announced that it has partnered with Clinilabs Drug Development Corporation to carry out the Company’s Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system